These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33445855)

  • 61. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
    Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
    Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 63. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
    Sorour Y; Dalley CD; Snowden JA; Cross NC; Reilly JT
    Br J Haematol; 2009 Jul; 146(2):225-7. PubMed ID: 19466970
    [No Abstract]   [Full Text] [Related]  

  • 65. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
    Curto-Barredo L; Segura S; Ishii N; Hashimoto T; Mascaró JM; Espinet B; Besses C; Pujol RM
    J Dermatol; 2019 Jun; 46(6):531-534. PubMed ID: 31021002
    [TBL] [Abstract][Full Text] [Related]  

  • 66.
    Sato M; Kato R; Jokoji R; Tachibana I
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34045202
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Detection of FIP1L1-PDGFRA fusion gene-positive cells in the skin lesion of a patient with hypereosinophilic syndrome.
    Kitayama S; Makino T; Yoto A; Mori S; Furukawa F; Torai R; Mizawa M; Shimizu T
    Clin Exp Dermatol; 2023 Mar; 48(4):364-367. PubMed ID: 36763740
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
    Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
    Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
    Kobayashi M; Kubota T; Uemura Y; Taguchi H
    Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
    Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib.
    Volz HC; Weiss C; Lossnitzer D; Zankl AR; Perz JB; Dengler TJ; Katus HA; Hardt SE
    Int J Cardiol; 2011 Sep; 151(3):e90-2. PubMed ID: 20609486
    [No Abstract]   [Full Text] [Related]  

  • 76. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
    Helbig G; Stella-Hołowiecka B; Hołowiecki J
    Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
    [No Abstract]   [Full Text] [Related]  

  • 77. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
    Breccia M; Cilloni D; Cannella L; Stefanizzi C; Tafuri A; Fama A; Santopietro M; Saglio G; Alimena G
    Cancer Chemother Pharmacol; 2009 May; 63(6):1161-3. PubMed ID: 18989670
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.
    Václavík J; Szotkowski T; Hutyra M; Kozák J; Lukl J; Táborský M
    Am J Hematol; 2010 Apr; 85(4):296-9. PubMed ID: 20169542
    [No Abstract]   [Full Text] [Related]  

  • 79. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.
    Gorantla SP; Zirlik K; Reiter A; Yu C; Illert AL; Von Bubnoff N; Duyster J
    Leukemia; 2015 Aug; 29(8):1763-70. PubMed ID: 25761934
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript.
    Halaburda K; Prejzner W; Szatkowski D; Limon J; Hellmann A
    Bone Marrow Transplant; 2006 Aug; 38(4):319-20. PubMed ID: 16819435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.